Propanc Biopharma, Inc.
PPCB
$1.95
-$0.20-9.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.07M | 159.00K | 229.10K | 207.50K | 355.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.13M | 213.40K | 290.80K | 259.90K | 420.90K |
| Operating Income | -53.13M | -213.40K | -290.80K | -259.90K | -420.90K |
| Income Before Tax | -54.07M | -430.20K | -354.30K | -358.80K | -527.00K |
| Income Tax Expenses | -- | -- | -- | -200.00 | -300.00 |
| Earnings from Continuing Operations | -54.07M | -430.20K | -354.30K | -358.60K | -526.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.07M | -430.20K | -354.30K | -358.60K | -526.70K |
| EBIT | -53.13M | -213.40K | -290.80K | -259.90K | -420.90K |
| EBITDA | -53.13M | -213.30K | -290.70K | -259.90K | -420.80K |
| EPS Basic | -12.50 | -32.23 | -- | -- | -- |
| Normalized Basic EPS | -7.69 | -19.27 | -- | -- | -- |
| EPS Diluted | -12.50 | -32.23 | -- | -- | -- |
| Normalized Diluted EPS | -7.69 | -19.27 | -- | -- | -- |
| Average Basic Shares Outstanding | 4.33M | 13.30K | -- | -- | -- |
| Average Diluted Shares Outstanding | 4.33M | 13.30K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |